Phase 2 clinical trials started on PRO 140

AIDS Patient Care STDS. 2008 Feb;22(2):159-60.
No abstract available

Publication types

  • News

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Clinical Trials, Phase II as Topic
  • Dose-Response Relationship, Drug
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / therapeutic use*
  • Female
  • HIV Antibodies / adverse effects
  • HIV Antibodies / therapeutic use*
  • HIV Infections / drug therapy*
  • Humans
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Male
  • Maximum Tolerated Dose
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Drugs, Investigational
  • HIV Antibodies
  • leronlimab